Page 11 - Bharat Biotech

Related party risks

Bharat Bio-Brazil investigation reveals dangers of offshore agencies

Best of BS Opinion: Related party risks, a new green wave of growth & more

Here are the best of Business Standard's opinion pieces for Wednesday

Bharat Biotech-Brazil row: Covaxin nod under controlled conditions

The agency said the suspension - which put the EUA application on ice - was due to missing data from the vaccine's clinical trials

A bottleneck in the vaccine chain

Prosenjit Datta points to a possible crisis as the government moves to improve supplies of Covid vaccines: inadequate testing facilities to handle those volumes

Covaxin 77.8% effective against symptomatic Covid-19: Bharat Biotech

The company claimed Covaxin is the first to report promising efficacy against asymptomatic infections based on qPCR testing that will help in reducing disease transmission

Covaxin 77.8% effective against symptomatic Covid-19, says Bharat Biotech

The analysis also found that Covaxin is 93.4 per cent effective against severe symptomatic Covid-19

Decision on Covaxin approval by August second week: WHO chief scientist

Developed by Bharat Biotech and the ICMR, Covaxin was approved by the Indian drug controller in January, and has been in use since

Decoded: Why Brazilian govt is under scrutiny over Bharat Biotech vaccine

The Brazilian media has reported that though Bharat Biotech initially quoted a price of $1.34 per dose, the Brazilian govt agreed to pay $15 per shot, having ignored Pfizer's offer at a lower price

Haven't received any payment from Brazilian health ministry: Bharat Biotech

Madison Biotech was founded by Krishna Ella in 2020 for external R&D, sales and marketing of vaccines

Brazil suspends $324-mn Covid-19 vaccine deal with Bharat Biotech

The deal to buy 20 million doses of Bharat Biotech's Covaxin shot has become a headache for Bolsonaro after whistleblowers went public with alleged irregularities

Covaxin effectively neutralises Alpha, Delta variants of Covid, says NIH

Covaxin, developed by Bharat Biotech in collaboration with the ICMR, effectively neutralises both Alpha and Delta variants of coronavirus, US' National Institute of Health has said

Top headlines: SC orders compensation for Covid dead, discoms get help

Business Standard brings you the top news of the evening

Bharat Biotech says regulatory steps taken for Brazil vaccine contract

Bharat Biotech said it followed a "step-by-step" approach for the regulatory approval and supply contract of its Covid vaccine in Brazil, and it has not received advance payments

Blurred picture

The sharp cuts in vaccine supply projections are baffling

Bolsonaro linked to alleged corruption in buying of Bharat Bio's vaccine

Brazil senate probing the president's handling of the pandemic; country signed a contract with the Indian firm to purchase 20 million doses for $325 million.

Bolsonaro says Brazil didn't spend cent on Bharat Bio vax deal under probe

Brazil officials are investigating the deal with the Indian company, citing the fact that the government struck a speedy agreement and ignored offers from Pfizer in 2020.

A jab at veracity

States should not aim to artificially push vaccination numbers

Brazil probes Health Ministry deal to buy 20 mn Covaxin vaccine doses

Brazil's federal prosecutor's office is investigating possible irregularities in a Health Ministry contract to purchase 20 million doses of the Covaxin vaccine manufactured by Bharat Biotech

Top headlines: Auto,IT lead advance tax payment; Covaxin shows 77% efficacy

Strap: Business Standard brings you the top headlines on Wednesday

Bharat Biotech's Covaxin shows over 77% efficacy in phase 3 trials

The vaccine has shown an efficacy rate of 93 per cent against severe disease and 60 per cent against asymptomatic Covid-19